QLS 12004
Alternative Names: QLS-12004Latest Information Update: 21 Jun 2023
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 03 May 2023 Preclinical trials in Solid tumours in China (unspecified route)
- 17 Apr 2023 Qilu Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease) in China (NCT05829616)